News

 

Component in Green Tea May Reduce Prostate Cancer in Men at High Risk

Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,000 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention, or the use of agents to prevent the development or progression of prostate cancer.

A team of researchers led by Nagi B. Kumar, PhD, RD, FADA, at Moffitt Cancer Center recently published results of a randomized trial that assessed the safety and effectiveness of the active components in green tea to prevent prostate cancer development in men who have premalignant lesions. The results were presented at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, and published online ahead of print April 14 in the journal Cancer Prevention Research.

Twenty percent of green tea is consumed in Asian countries where prostate cancer death rates are among the lowest in the world, and the risk of prostate cancer appears to be increased among Asian men who abandon their original dietary habits after migrating to the United States.

Laboratory studies have shown that substances in green tea, called catechins, inhibit cancer cell growth, motility, and invasion, and stimulate cancer cell death. Green tea catechins also prevent and reduce tumor growth in animal models. Epigallocatechin-3-gallate (EGCG) is the most abundant and potent catechin found in green tea responsible for these cancer prevention effects.

The goal of this trial was to evaluate if a one-year intervention with green tea catechins could suppress prostate cancer development in men who had high-grade prostatic intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation (ASAP). The researchers used decaffeinated green tea capsules called Polyphenon E that contained a mixture of catechins that predominantly contained EGCG at a dose of 200 mg twice per day.

The researchers compared Polyphenon E in 49 men with placebo tablets in 48 men over a one-year treatment period. Overall, the difference in the number of prostate cancer cases at the end of one year between the two treatment groups wasn't statistically significant. However, in men who only had HGPIN at the beginning of the trial, they observed a lower combined rate of ASAP and prostate cancer development with Polyphenon E. ASAP is an entity that reflects a broad group of lesions in the prostate with insufficient changes in the cells to be definitively diagnosed as prostate cancer. In addition, men on Polyphenon E had a significant decrease in prostate-specific antigen (PSA) levels. PSA is a biomarker that, in combination with other risk factors, is used to screen patients for prostate cancer, and high levels signify a higher risk of prostate cancer.

The Moffitt researchers observed a significant increase in the levels of EGCG in the blood plasma of men on Polyphenon E, and the capsules at this dose were tolerated in this group of men.

— Source: Moffitt Cancer Center

ADVERTORIAL